Evangelia Emmanouilidou

Dr. Evangelia Emmanouilidou

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2019 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
ELEmmanouela Leandrou
Emmanouela Leandrou
Evangelia EmmanouilidouEvangelia Emmanouilidou
Evangelia Emmanouilidou
KVKOSTAS VEKRELLIS
KOSTAS VEKRELLIS
α-synuclein (α-syn) is biochemically and genetically linked to Parkinson’s disease (PD) and other synucleinopathies. It is now widely accepted that a-syn can be released in the extracellular space, even though the mechanism of its release is still unclear. In addition, pathology-related aggregated species of α-synuclein have been shown to propagate between neurons in synaptically connected areas of the brain thereby assisting the spreading of pathology in healthy neighbouring neuronal cells. In neurons, calcium channels are key signaling elements that modulate the release of bioactive molecules (hormones, proteins, neurotransmitters) through calcium sensing. Such calcium sensing activity is determined by the distinct biophysical and pharmacological properties and the ability of calcium channels to interact with other modulatory proteins. Although the function of extracellular α-synuclein is currently unknown, previous work suggested the presence of a calcium-dependent mechanism for α-syn secretion both in vitro, in neuronal cells in culture, and also in vivo, in the context of a trans-neuronal network in brain. Mechanisms regulating extracellular a-syn levels may be of particular importance as they could represent novel therapeutic targets. We discuss here how calcium channel activity may contribute to a-syn aggregation and secretion as a pathway to disease progression in synucleinopathies.

21 February 2024 in Translational Neurodegeneration
Verified
Journal Article
Open access
PDF file
ELEmmanouela Leandrou
Emmanouela Leandrou
ICIoanna Chalatsa
Ioanna Chalatsa
DADimitrios Anagnostou
Dimitrios Anagnostou
CMChristina Machalia
Christina Machalia
MSMaria Semitekolou
Maria Semitekolou
Evangelia EmmanouilidouEvangelia Emmanouilidou
Evangelia Emmanouilidou
Background: It is now realized that Parkinson’s disease (PD) pathology extends beyond the substantia nigra, affecting both central and peripheral nervous systems, and exhibits a variety of non-motor symptoms often preceding motor features. Neuroinflammation induced by activated microglia and astrocytes is thought to underlie these manifestations. α-Synuclein aggregation has been linked with sustained neuroinflammation in PD, aggravating neuronal degeneration; however, there is still a lack of critical information about the structural identity of the α-synuclein conformers that activate microglia and/or astrocytes and the molecular pathways involved. Methods: To investigate the role of α-synuclein conformers in the development and maintenance of neuroinflammation, we used primary quiescent microglia and astrocytes, post-mortem brain tissues from PD patients and A53T α-synuclein transgenic mice that recapitulate key features of PD-related inflammatory responses in the absence of cell death, i.e., increased levels of pro-inflammatory cytokines and complement proteins. Biochemical and -omics techniques including RNAseq and secretomic analyses, combined with 3D reconstruction of individual astrocytes and live calcium imaging, were used to uncover the molecular mechanisms underlying glial responses in the presence of α-synuclein oligomers in vivo and in vitro. Results: We found that the presence of SDS-resistant hyper-phosphorylated α-synuclein oligomers, but not monomers, was correlated with sustained inflammatory responses, such as elevated levels of endogenous antibodies and cytokines and microglial activation. Similar oligomeric α-synuclein species were found in post-mortem human brain samples of PD patients but not control individuals. Detailed analysis revealed a decrease in Iba1Low/CD68Low microglia and robust alterations in astrocyte number and morphology including process retraction. Our data indicated an activation of the p38/ATF2 signaling pathway mostly in microglia and a sustained induction of the NF-κB pathway in astrocytes of A53T mice. The sustained NF-κB activity triggered the upregulation of astrocytic T-type Cav3.2 Ca2+ channels, altering the astrocytic secretome and promoting the secretion of IGFBPL1, an IGF-1 binding protein with anti-inflammatory and neuroprotective potential. Conclusions: Our work supports a causative link between the neuron-produced α-synuclein oligomers and sustained neuroinflammation in vivo and maps the signaling pathways that are stimulated in microglia and astrocytes. It also highlights the recruitment of astrocytic Cav3.2 channels as a potential neuroprotective mediator against the α-synuclein-induced neuroinflammation. Graphical

27 June 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
DADimitrios Anagnostou
Dimitrios Anagnostou
GSGarifalia Sfakianaki
Garifalia Sfakianaki
KMKaterina Melachroinou
Katerina Melachroinou
MSMiltiadis Soutos
Miltiadis Soutos
VCVasilios C Constantinides
Vasilios C Constantinides
Evangelia EmmanouilidouEvangelia Emmanouilidou
Evangelia Emmanouilidou
Even though it is currently well-established that α-synuclein aggregation is closely associated with the pathological events in Parkinson’s disease (PD) and several other neurodegenerative disorders, collectively called synucleinopathies, the mechanistic link between α-synuclein aggregates and the onset and progression of neurodegeneration in these diseases remain unclear. The process of aggregation initiates from a structurally distorted monomer that gradually oligomerizes to generate a repertoire of fibrillar and oligomeric multimers that deposit within diseased cells in the brain. Total α-synuclein has been proposed as a potential biomarker in PD, but most of the studies do not discriminate between distinct α-synuclein conformers. To correlate protein measurements to disease pathology, we have developed a conformation-specific ELISA method that selectively detects fibrillar and oligomeric forms of α-synuclein without cross-reacting with monomers. We have used this assay to determine the levels of aggregated α-synuclein in human and mouse brain tissue as well as in CSF and CSF-derived exosomes from patients with synucleinopathy and control subjects. Our results verify the ability of the new assay to detect aggregated α-synuclein in complex matrices and support the idea that the levels of these conformers are related to the age of onset in PD patients, while CSF analysis showed that these species exist in low abundance in CSF and CSF-derived exosomes. Future studies will be required to fully assess the diagnostic usefulness of this ELISA in synucleinopathies.

6 February 2025 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
KDKonstantina Dimoula
Konstantina Dimoula
Nikolaos PapagiannakisNikolaos Papagiannakis
Nikolaos Papagiannakis
MMMatina Maniati
Matina Maniati
LSLeonidas Stefanis
Leonidas Stefanis
Evangelia EmmanouilidouEvangelia Emmanouilidou
Evangelia Emmanouilidou
Mostly known for its implication in synucleinopathies, including Parkinson's disease (PD), α-synuclein is predominantly expressed in the nervous system. Most of the peripheral α-synuclein is found in erythrocytes, and several studies have examined a possible association between erythrocytic α-synuclein and PD. We have used a recently developed ELISA that selectively detects fibrillar and oligomeric α-synuclein to measure aggregated α-synuclein in red blood cells (RBCs) collected from PD patients and age/sex-matched control individuals (n = 35). The PD group included patients without any common mutation (genetically undetermined group, GU-PD, n = 56) as well as mutation carriers in the α-synuclein gene (A53T-PD, n = 28) and glucocerebrosidase gene (GBA-PD, n = 24). We found that the concentration of aggregated α-synuclein in erythrocytes was significantly increased in GU-PD patients compared to controls. A53T-PD and GBA-PD patients exhibited similar levels of erythrocytic aggregated α-synuclein as the control group. The levels of fibrillar/oligomeric α-synuclein in RBCs were reduced in respect to the age of control individuals suggesting that the observed increase in the GU-PD cohort was not due to normal aging. Parallel assessment of monomeric α-synuclein revealed that aggregated, but not total, α-synuclein could discriminate PD patients from control individuals. The elevation of aggregated α-synuclein in GU-PD erythrocytes, which is not related to aging, suggests that these forms may be indicative of PD pathology and possibly accumulate upon disease establishment. As such, aggregated α-synuclein in RBCs could be a potential biomarker for PD diagnosis.

15 September 2020 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MXMary Xylaki
Mary Xylaki
IBIoanna Boumpoureka
Ioanna Boumpoureka
MKMaroula G. Kokotou
Maroula G. Kokotou
TMTheodoros Marras
Theodoros Marras
GPGeorgia Papadimitriou
Georgia Papadimitriou
Evangelia EmmanouilidouEvangelia Emmanouilidou
Evangelia Emmanouilidou
Parkinson's disease is biochemically characterized by the deposition of aberrant aggregated α‐synuclein in the affected neurons. The aggregation properties of α‐synuclein greatly depend on its affinity to bind cellular membranes via a dynamic interaction with specific lipid moieties. In particular, α‐synuclein can interact with arachidonic acid (AA), a polyunsaturated fatty acid, in a manner that promotes the formation of α‐helix enriched assemblies. In a cellular context, AA is released from membrane phospholipids by phospholipase A 2 (PLA 2 ). To investigate the impact of PLA 2 activity on α‐synuclein aggregation, we have applied selective PLA 2 inhibitors to a SH‐SY5Y cellular model where the expression of human wild‐type α‐synuclein is correlated with a gradual accumulation of soluble oligomers and subsequent cell death. We have found that pharmacological and genetic inhibition of GIVA cPLA 2 resulted in a dramatic decrease of intracellular oligomeric and monomeric α‐synuclein significantly promoting cell survival. Our data suggest that alterations in the levels of free fatty acids, and especially AA and adrenic acid, promote the formation of α‐synuclein conformers which are more susceptible to proteasomal degradation. This mechanism is active only in living cells and is generic since it does not depend on the absolute quantity of α‐synuclein, the presence of disease‐linked point mutations, the expression system or the type of cells. Our findings indicate that the α‐synuclein‐fatty acid interaction can be a critical determinant of the conformation and fate of α‐synuclein in the cell interior and, as such, cPLA 2 inhibitors could serve to alleviate the intracellular, potentially pathological, α‐synuclein burden.

6 July 2024 in Molecules
Verified
Journal Article
Open access
PDF file
AKAfroditi Kokkosi
Afroditi Kokkosi
EGElpida Garofallidou
Elpida Garofallidou
NZNIkolaos Zacharopoulos
NIkolaos Zacharopoulos
Nikolaos TsoureasNikolaos Tsoureas
Nikolaos Tsoureas
KDKonstantina Diamanti
Konstantina Diamanti
Athanassios |I PhilippopoulosAthanassios |I Philippopoulos
Athanassios |I Philippopoulos
Organometallic complexes of the formula [Ru(N^N)(p-cymene)Cl][X] (N^N = bidentate polypyridyl ligands, p-cymene = 1-methyl-4-(1-methylethyl)-benzene, X = counter anion), are currently studied as possible candidates for the potential treatment of cancer. Searching for new organometallic compounds with good to moderate cytotoxic activities, a series of mononuclear water-soluble ruthenium(II)–arene complexes incorporating substituted pyridine–quinoline ligands, with pending -CH2OH, -CO2H and -CO2Me groups in the 4-position of quinoline ring, were synthesized, for the first time, to study their possible effect to modulate the activity of the ruthenium p-cymene complexes. These include the [Ru(η6-p-cymene)(pqhyme)Cl][X] (X = Cl− (1-Cl), PF6− (1-PF6), pqhyme = 4-hydroxymethyl-2-(pyridin-2-yl)quinoline), [Ru(η6-p-cymene)(pqca)Cl][Cl] ((2-Cl), pqca = 4-carboxy-2-(pyridin-2-yl)quinoline), and [Ru(η6-p-cymene)(pqcame)Cl][X] (X = Cl− (3-Cl), PF6− (3-PF6), pqcame = 4-carboxymethyl-2-(pyridin-2-yl)quinoline) complexes, respectively. Identification of the complexes was based on multinuclear NMR and ATR-IR spectroscopic methods, elemental analysis, conductivity measurements, UV–Vis spectroscopic, and ESI-HRMS techniques. The solid-state structures of 1-PF6 and 3-PF6 have been elucidated by single-crystal X-ray diffraction revealing a three-legged piano stool geometry. This is the first time that the in vitro cytotoxic activities of these complexes are studied. These were conducted in HEK293T (human embryonic kidney cells) and HeLa cells (cervical cancer cells) via the MTT assay. The results show poor in vitro anticancer activities for the HeLa cancer cell lines and 3-Cl proved to be the most potent (IC50 > 80 μΜ). In both cell lines, the cytotoxicity of the ligand precursor pqhyme is significantly higher than that of cisplatin.